Windlas Biotech Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹80(17.39%)
Premium (ELP)
Windlas Biotech Limited's completed its IPO journey with a successful listing on NSE, BSE on Aug 16, 2021. The public offering mobilized 87,29,023 Shares in total capital, comprising 35,86,956 Shares in fresh equity and ₹237.00 Cr in Offer for Sale shares from existing stakeholders.
The offering was conducted within the price band of ₹448 to ₹460, with minimum application lots of 30 shares. Investor participation during the Aug 04, 2021 to Aug 06, 2021 subscription window determined the final allocation pattern.
The basis of allotment was announced on Aug 11, 2021, finalizing share distribution to successful applicants. The listing represents a significant corporate development, providing the company with enhanced visibility and access to public capital markets.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Incorporated in 2001, Windlas Biotech Ltd is a prominent pharmaceutical company in India’s CDMO segment, offering end-to-end services from product discovery and development to licensing and commercial manufacturing of generic and complex generic products. The company also markets its own branded products in the trade generics and OTC segments, focusing on chronic therapeutic categories related to lifestyle disorders. Windlas Biotech operates across three verticals: CDMO services, domestic trade generics and nutraceuticals, and exports. Its marquee clients include Pfizer, Sanofi India, Cadila Healthcare, Emcure Pharmaceuticals, Eris Lifesciences, Intas Pharmaceuticals, and Systopic Laboratories. The company’s Dehradun-based manufacturing facilities have an installed capacity of 7,063.83 million tablets/capsules, 54.46 million pouches/sachets, and 61.08 million liquid bottles.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Leading CDMO Player: Top company in India’s pharmaceutical formulation CDMO segment.
- Therapeutic Focus: Strong emphasis on chronic therapy products.
- Advanced Facilities: State-of-the-art manufacturing units in Dehradun, Uttarakhand.
- Experienced Leadership: Professional promoters supported by a skilled senior management team.
- Innovative Portfolio: Offers complex generic products.
- Strong Financials: Demonstrates a robust track record of financial performance.
NA
- Ashok Kumar Windlass
- Hitesh Windlass
- Manoj Kumar Windlass
- AKW WBL Family Pvt Trust
Windlas Biotech Limited
Link Intime India Private Limited